The neurochemical and behavioral effects of the novel cholinesterase- monoamine oxidase inhibitor, ladostigil, in response to L-dopa and L-tryptophan, in rats

British Journal of Pharmacology

Volumn 146, Issue 4, 2005, Pages 553-560

  Sagi, Yotam ^a   Driguès, Noam ^a   Youdim, Moussa B H ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Catecholamine; Cholinesterase inhibitor; Dementia with Lewy bodies; Ladostigil; Monoamine oxidase inhibitor; Motor activity; Multifunctional drug therapy; Serotonin; Stereotypy

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; AMINE; AMINE OXIDASE (FLAVIN CONTAINING); CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DOPAMINE; LADOSTIGIL; LEVODOPA; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; MONOAMINE OXIDASE INHIBITOR; MUSCARINIC RECEPTOR; NEUROTRANSMITTER; RIVASTIGMINE; SCOPOLAMINE; SEROTONIN; TRANYLCYPROMINE; TRYPTOPHAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLINERGIC ACTIVITY; CHOLINERGIC TRANSMISSION; CHRONIC DRUG ADMINISTRATION; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; CORPUS STRIATUM; DEMENTIA; DRUG EFFECT; DRUG RESPONSE; ENZYME ACTIVITY; ENZYME INHIBITION; HIPPOCAMPUS; HYPERACTIVITY; LEWY BODY; LOCOMOTION; MALE; NEUROCHEMISTRY; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; RAT; STEREOTYPY;

ANIMALS; BASAL GANGLIA; BEHAVIOR, ANIMAL; CARBAMATES; CHOLINESTERASE INHIBITORS; DOPAMINE; HIPPOCAMPUS; HYPERKINESIS; INDANS; LEVODOPA; LEWY BODY DISEASE; MALE; MONOAMINE OXIDASE INHIBITORS; MOTOR ACTIVITY; MUSCARINIC ANTAGONISTS; NOREPINEPHRINE; PHENYLCARBAMATES; RATS; RATS, SPRAGUE-DAWLEY; SCOPOLAMINE; SEROTONIN; TIME FACTORS; TRANYLCYPROMINE; TRYPTOPHAN;

EID: 27144489695     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706355     Document Type: Article

References (47)

1. BEN-SHACHAR, D. & YOUDIM, M.B.H. (1990). Selectivity of melaninized nigra-striatal dopamine neurons to degeneration in Parkinson's disease may depend on iron-melanin interaction. J. Neural Transm. Suppl., 29, 251-258.
2. CALABRESI, P., CENTONZE, D., GUBELLINI, P. & BERNARDI, G. (1999). Activation of M1-like muscarinic receptors is required for the induction of corticostriatal LTP. Neuropharmacology, 38, 323-326.
3. CALABRESI, P., CENTONZE, D., GUBELLINI, P., PISANI, A. & BERNARDI, G. (2000). Acetylcholine-mediated modulation of striatal function. Trends Neurosci., 23, 120-126.
4. CARRIERO, D.L., OUTSLAY, G., MAYORGA, A.J., ABERMAN, J., GIANUTSOS, G. & SALAMONE, J.D. (1997). Motor dysfunction produced by tacrine administration in rats. Pharmacol. Biochem. Behav., 58, 851-858.
5. DAS, A., DIKSHIT, M. & NATH, C. (2001). Profile of acetylcholinesterase in brain areas of male and female rats of adult and old age. Life Sci., 68, 1545-1555.
6. DAVIS, K.L. & ROSENBERG, G.S. (1981). Induction of behavioral supersensitivity to apomorphine by DFP treatment. Life Sci., 28, 1953-1959.
7. DE SOUZA, H. & PALERMO-NETO, J. (1982). A quantitative study of cholinergic-dopaminergic interactions in the central nervous system. Pharmacology, 24, 222-229.
8. ELLMAN, G.L., COURTNEY, K.D., ANDRES JR, V. & FEATHER-STONE, R.M. (1961). A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol., 7, 88-95.
9. GAO, Z.G., CUI, W.Y. & LIU, C.G. (1997). Modulation of apomorphine-induced rotations in unilaterally 6-hydroxydopamine lesioned rats by cholinergic agonists and antagonists. Life Sci., 60, 317-323.
10. GERBER, D.J., SOTNIKOVA, T.D., GAINETDINOV, R.R., HUANG, S.Y., CARON, M.G. & TONEGAWA, S. (2001). Hyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor-deficient mice. Proc. Natl. Acad. Sci. U.S.A., 98, 15312-15317.
11. GONZALEZ, L.P. & ELLINWOOD JR, E.H. (1984). Cholinergic modulation of stimulant-induced behavior. Pharmacol. Biochem. Behav., 20, 397-403.
12. GRACE, J., DANIEL, S., STEVENS, T., SHANKAR, K.K., WALKER, Z., BYRNE, E.J., BUTLER, S., WILKINSON, D., WOOLFORD, J., WAITE, J. & MCKEITH, I.G. (2001). Long-term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial. Int. Psychogeriatr., 13, 199-205.
13. GRAHAME-SMITH, D. (1971). Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan. J. Neurochem., 18, 1053-1066.
14. GREEN, A.R., MITCHELL, B.D., TORDOFF, A.F. & YOUDIM, M.B.H. (1977). Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine. Br. J. Pharmacol., 60, 343-349.
15. GREEN, A.R. & YOUDIM, M.B.H. (1975). Effects of monoamine oxidase inhibition by clorgyline, deprenil or tranylcypromine on 5-hydroxytryptamine concentrations in rat brain and hyperactivity following subsequent tryptophan administration. Br. J. Pharmacol., 55, 415-422.
16. GROUP, P.S. (2004). A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch. Neurol., 61, 561-566.
17. INGLIS, F. (2002). The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. Int. J. Clin. Pract. Suppl., 127, 45-63.
18. IZZO, P.N. & BOLAM, J.P. (1988). Cholinergic synaptic input to different parts of spiny striatonigral neurons in the rat. J. Comp. Neurol., 269, 219-234.
19. JOYCE, E.M. & KOOB, G.F. (1981). Amphetamine-, scopolamine- and caffeine-induced locomotor activity following 6-hydroxydopamine lesions of the mesolimbic dopamine system. Psychopharmacology (Berl.), 73, 311-313.
20. KAUFER, D.I. (2004). Pharmacologic treatment expectations in the management of dementia with Lewy bodies. Dement. Geriatr. Cogn. Disord., 17 (Suppl. 1), 32-39.
21. KAWAGUCHI, Y. (1997). Neostriatal cell subtypes and their functional roles. Neurosci. Res., 27, 1-8.
22. KELLER, R., OKE, A., MEFFORD, I. & ADAMS, R.N. (1976). Liquid chromatographic analysis of catecholamines routine assay for regional brain mapping. Life Sci., 19, 995-1003.
23. LAMENSDORF, I., YOUDIM, M.B.H. & FINBERG, J.P. (1996). Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo. J. Neurochem., 67, 1532-1539.
24. LEHMANN, J. & LANGER, S.Z. (1983). The striatal cholinergic interneuron: synaptic target of dopaminergic terminals? Neuroscience, 10, 1105-1120.
25. MAITRE, L., WALDMEIER, P.C. & DELINI-STULA, A. (1976). Relations between the degree of monoamine oxdase inhibition and some psycopharmacological responses to monoamine oxidase inhibition in rats. Ciba Found. Study Group, 39, 247-267.
26. MENEGUZ, A., BISSO, G.M. & MICHALEK, H. (1992). Age-related changes in acetylcholinesterase and its molecular forms in various brain areas of rats. Neurochem. Res., 17, 785-790.
27. MOSIMANN, U. & MCKEITH, I. (2003). Dementia with lewy bodies - diagnosis and treatment. Swiss Med. Wkly., 133, 131-142.
28. OLDS, M.E., FOBES, J.L. & ALBERT, V. (1981). Catecholamine-serotonin interaction effects on activity in rats neonatally treated with 6-hydroxydopamine. Psychopharmacology (Berl.), 73, 31-33.
29. OLIANAS, M.C., ONALI, P., NEFF, N.H. & COSTA, E. (1983). Muscarinic receptors modulate dopamine-activated adenylate cyclase of rat striatum. J. Neurochem., 41, 1364-1369.
30. PALUMBO, G., BACCHI, S., COPPOLINO, M.F. & PANTALEONI, G.C. (2001). Neurochemical and behavioural effects of chronic aldicarb administration in rats. Pharmacol. Toxicol., 89, 249-254.
31. PIGGOTT, M.A., MARSHALL, E.F., THOMAS, N., LLOYD, S., COURT, J.A., JAROS, E., BURN, D., JOHNSON, M., PERRY, R.H., MCKEITH, I.G., BALLARD, C. & PERRY, E.K. (1999). Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution. Brain, 122, 1449-1468.
32. PIGGOTT, M.A., OWENS, J., O'BRIEN, J., COLLOBY, S., FENWICK, J., WYPER, D., JAROS, E., JOHNSON, M., PERRY, R.H. & PERRY, E.K. (2003). Muscarinic receptors in basal ganglia in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease. J. Chem. Neuroanat., 25, 161-173.
33. RAKONCZAY, Z. (2003). Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain. Acta Biol. Hung., 54, 183-189.
34. RASTOGI, S.K., RASTOGI, R.B., SINGHAL, R.L. & LAPIERRE, Y.D. (1982). Effects of cholinergic and GABAergic drugs on apomorphine-induced gnawing behavior in rats. Biol. Psychiatry, 17, 937-946.
35. SAGI, Y., WEINSTOCK, M. & YOUDIM, M.B. (2003). Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor. J. Neurochem., 86, 290-297.
36. SCALI, C., CASAMENTI, F., BELLUCCI, A., COSTAGLI, C., SCHMIDT, B. & PEPEU, G. (2002). Effect of subchronic administration of metrifonate, rivastigmine and donepezil on brain acetylcholine in aged F344 rats. J. Neural Transm., 109, 1067-1080.
37. SHANNON, H.E. & PETERS, S.C. (1990). A comparison of the effects of cholinergic and dopaminergic agents on scopolamine-induced hyperactivity in mice. J. Pharmacol. Exp. Ther., 255, 549-553.
38. SIPOS, M.L., BURCHNELL, V. & GALBICKA, G. (1999). Dose-response curves and time-course effects of selected anticholinergics on locomotor activity in rats. Psychopharmacology (Berl.), 147, 250-256.
39. STERLING, J., HERZIG, Y., GOREN, T., FINKELSTEIN, N., LERNER, D., GOLDENBERG, W., MISKOLCZI, I., MOLNAR, S., RANTAL, F., TAMAS, T., TOTH, G., ZAGYVA, A., ZEKANY, A., LAVIAN, G., GROSS, A., FRIEDMAN, R., RAZIN, M., HUANG, W., KRAIS, B., CHOREV, M., YOUDIM, M.B. & WEINSTOCK, M. (2002). Novel dual inhibitors of AchE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease. J. Med. Chem., 45, 5260-5279.
40. SUGITA, S., UCHIMURA, N., JIANG, Z.G. & NORTH, R.A. (1991). Distinct muscarinic receptors inhibit release of gamma-aminobutyric acid and excitatory amino acids in mammalian brain. Proc. Natl. Acad. Sci. U.S.A., 88, 2608-2611.
41. TIPTON, K.F. & YOUDIM, M.B. (1976). Assay of monoamine oxidase. In: Monoamine Oxidase and Its Inhibition. Excerpta Medica, ed. Wolstenholeme, G.E.W. & Knight, J. pp 393-403. Amsterdam, Holland.
42. WEINSTOCK, M., BEJAR, C., WANG, R.H., POLTYREV, T., GROSS, A., FINBERG, J.P. & YOUDIM, α (2000a). TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease. J. Neural Transm. Suppl., 60, 157-169.
43. WEINSTOCK, M., GOREN, T. & YOUDIM, M.B.H. (2000b). Development of a novel neuroprotective drug (TV3326) for the treatment of alzheimer's disease, with cholinesterase and monoamine oxidase inhibitory activities. Drug Dev. Res., 50, 216-222.
44. WEINSTOCK, M., GORODETSKY, E., POLTYREV, T., GROSS, A., SAGI, Y. & YOUDIM, M. (2003). A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry, 27, 555-561.
45. WOLTHUIS, O.L. & VANWERSCH, R.A. (1984). Behavioral changes in the rat after low doses of cholinesterase inhibitors. Fund. Appl. Toxicol., 4, S195-S208.
46. YOUDIM, M.B.H., WADIA, A., TATTON, N.A. & WEINSTOCK, M. (2001). The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. Ann. NY Acad. Sci., 939, 450-458.
47. YOUDIM, M.B.H. & WEINSTOCK, M. (2002). Molecular basis of neuroprotective activities of rasagline and the anti alzheimer drug, TV3326, [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]. Cell. Mol. Neurobiol., 21, 555-573.